MEDP Stock Analysis: Buy, Sell, or Hold?
MEDP - Medpace Holdings, Inc. Common Stock
$450.82
5.23 (1.17%)
▲
5d:
+5.33%
30d:
+8.1%
90d:
-3.23%
BUY
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Jul 20, 2026
Get Alerted When MEDP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MEDP shows positive signals but monitor for confirmation. Market pricing in 4.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: MEDP shows positive signals but monitor for confirmation. Market pricing in 4.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$632.40
Based on 6.4% avg growth
INTRINSIC VALUE TODAY
$392.67
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MEDP is currently trading at $450.81, which is considered extended relative to its 30-day fair value range of $415.31 to $438.65. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.3) compared to its historical average (28.1). Remarkably, the market is currently pricing in an annual earnings decline of 4.8% over the next few years. This pessimistic expectation contrasts with the company's recent 16.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, MEDP is in a strong downtrend. The price is approaching resistance at $460.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MEDP has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MEDP is in a strong downtrend. The price is approaching resistance at $460.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MEDP has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$415.31 -
$438.65
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($442.83)
Trading Range Analysis
30-Day Trading Range
$415.31 -
$438.65
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$25.25
(5.6%)
Support & Resistance Levels
Support Level
$403.46
Resistance Level
$460.90
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.29
Wall Street Target
$442.83
(-1.8%)
Revenue Growth (YoY)
26.5%
Earnings Growth (YoY)
16.6%
Profit Margin
17.2%
Valuation Discount vs History
-4.8% cheaper
PE vs Historical
24.3 vs 28.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.8%
(market-implied from PE analysis)
1-Year Target
$429.18
(-5%)
2-Year Target
$408.58
(-9%)
3-Year Target
$388.96
(-14%)
3-Yr Target (if PE normalizes)
(PE: 24→28)
$450.03
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.3, Growth: 8.8%)
$580.17
(+29%)
Base:
(SPY PE: 21.9, Growth: 8.8%)
$523.38
(+16%)
Bear:
(PE: 18.6, Growth: 8.8%)
$444.88
(-1%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (28x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Trailing PE: 27.88 | Current EPS (TTM): $15.88
Bull Case
$569.17
(+27%)
Analyst growth 16.9%, PE expands to 30.7
Base Case
$517.43
(+16%)
Market implied 16.9%, PE stable at 27.9
Bear Case
$301.02
(-33%)
Severe decline -20.0%, PE contracts to 23.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.3 to 28.1
Stabilization Target:
$521.59
(+15.7%)
PE Expansion Potential:
+15.7%
Share & Embed Analysis
Last updated: June 04, 2026 5:28 AM ET
Data refreshes hourly during market hours. Next update: 6:28 AM
Data refreshes hourly during market hours. Next update: 6:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MEDP showing a specific setup today?
Insider Activity (6 Months)
2
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jesse J Geiger
SELL
31707 shares
2026-03-17
David Taylor
BUY
2026-02-26
David Taylor
BUY
2026-01-29
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$612 | 59 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$248 | 62 BUY |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 66 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$131 | 57 HOLD |
Advanced MEDP Option Strategies
Professional options setups generated by AI based on today's MEDP price and gamma walls.
